Validates the use of the RAPID score for predicting mortality in pleural infections, directly informing the management of patients undergoing pleural interventions like chest tubes and medical thoracoscopy.
IPBronch Review
🎯 Background & Rationale
- Clinical dilemma: Malignant pleural mesothelioma (MPM) is notoriously difficult to treat locally due to the distributed nature of the pleura and the high radiosensitivity of adjacent cardiopulmonary organs.
- Therapeutic evolution: Advances in radiation delivery technology (such as intensity-modulated radiation therapy and proton beam therapy) are expanding the feasibility of radiation therapy in both palliative and definitive multidisciplinary management.
👥 Study Design & Population
- Review article: This publication is a comprehensive narrative review synthesizing current evidence regarding adjuvant, neoadjuvant, and definitive radiation therapy for MPM.
- Target population: Patients with MPM managed across multidisciplinary care paradigms involving surgical cytoreduction, chemotherapy, and radiation therapy.
📈 Methodology & Rigor
- Literature synthesis: The authors review fundamentals of radiation radiobiology, historical 2D/3D conformal techniques, modern advanced photon modalities (intensity-modulated radiation therapy, volumetric modulated arc therapy), and proton beam therapy.
- Multimodality integration: Evaluates clinical data across different treatment schemas, including extrapleural pneumonectomy, extended pleurectomy/decortication, and palliative interventions.
🔬 Key Findings [or Planned Endpoints]
- Trimodality outcomes: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy and hemithoracic radiation yields median overall survivals ranging from 14–20 months on an intention-to-treat basis.
- Lung-sparing approaches: Lung-sparing pleurectomy/decortication combined with selective high-dose external pleural radiation (such as the IMPRINT study) reports median overall survivals between 23.7 and 33 months with reduced toxicity.
- Palliative efficacy: Palliative radiation therapy for pain provides objective response rates of 43% to 74% and significant pain score improvements in 47–69% of patients.
⚖️ Critical Appraisal
- Technological challenges: Steep learning curves exist for advanced photon and proton planning, with high-dose/low-dose radiation spread risking severe radiation pneumonitis if not meticulously optimized.
- Trial limitations: Landmark randomized trials (like SAKK 17/04) faced challenges with patient attrition, multi-center variability, and lack of radiation quality assurance.
💡 The Clinical Bottom Line
- Multidisciplinary necessity: Radiation therapy is no longer strictly palliative; when combined with modern surgical cytoreduction and systemic therapy, it plays a vital role in achieving durable local control.
- Procedural awareness: Interventional pulmonologists must remain cognizant of local recurrence patterns and the evolving role of prophylactic tract irradiation and targeted advanced radiotherapy.
Abstract
Abstract not available.
Keep reading
N opens the next oneUltrasound estimation of pleural fluid volume is a core procedural skill for thoracentesis and chest tube placement, making this directly relevant to IP practice.
Directly impacts pleural management and staging by maximizing the diagnostic yield of routine thoracentesis for molecular testing in malignancy.
Pleural fluid obtained during thoracentesis or medical thoracoscopy should be preserved for cfDNA molecular testing when tissue is limited.
Relevant to pleural disease management and post-procedural care of trapped or non-expandable lungs.
Provides useful risk stratification tools for managing secondary spontaneous pneumothorax patients who often require IP intervention.